DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rzjz2t/product_profiles) has announced the addition of the "Product Profiles: Asthma - Key Companies Act to Maintain Dominance" report to their offering.
Asthma is a well established market, but key unmet needs continue to drive development. While Advair (fluticasone/salmeterol) has market dominance, GlaxoSmithKline is racing to bring a once-daily follow-on product to market ahead of generic entry.
Asthma is an established and growing market dominated by key brands. However, competition is growing and generic threats are increasing, such that the market will become more fragmented. A number of pipeline products, notably once-daily ICS/LABA combinations, are expected to address unmet needs and have high clinical and commercial potential.
- Advair (GlaxoSmithKline) was the first ICS/LABA combination to launch but is expected to come under threat from generics and increasing competition, but with Phase III trials complete, its follow-on Relovair is on track to become the first once-daily ICS/LABA, which, if achieved, would ensure that the company maintains its market dominance.
- Several biologics have advanced in the pipeline. Genentech's lebrikizumab is currently in large Phase III trials looking at exacerbations and AstraZeneca's tralokinumab and benralizumab are both in Phase II. Biologics could address unmet needs for subsets of uncontrolled patients, but key opinion leaders maintain skepticism over their viability.
- Despite patent expiries for key ICS/LABA combinations, generics have not yet entered any of the seven major markets. Datamonitor believes that in the next couple of years they will launch as branded generics. Lower price discounts together with patients' hesitation to switch devices will help the brands resist generic erosion.
Reasons to Purchase:
- How do marketed treatments of asthma compare to one another and where will pipeline agents fit in?
- How is GlaxoSmithKline protecting its market position in the face of increasing competition and looming generic entry?
- How can companies position their products at launch in order to compete in this well established market?
- How is asthma treatment expected to change as novel therapies move through the pipeline?
Key Topics Covered:
MARKETED PRODUCT PROFILES
- Advair (fluticasone/salmeterol; GlaxoSmithKline)
- Singulair (montelukast; Merck & Co.)
- Symbicort (budesonide/formoterol; AstraZeneca)
- Dulera (mometasone/formoterol; Merck & Co.)
- Xolair (omalizumab; Genentech)
- Other marketed drugs for asthma
PIPELINE PRODUCT PROFILES
- Flutiform (fluticasone/formoterol; SkyePharma)
- Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline)
- Lebrikizumab (MILR1444A; Genentech)
- Masitinib (AB-1010; AB Science)
- QMF149 (mometasone/indacaterol; Novartis)
- Other pipeline drugs for asthma
For more information visit http://www.researchandmarkets.com/research/rzjz2t/product_profiles